Harvard Bioscience Inc. HBIO
Biotechnology: Laboratory Analytical Instruments · IPO 2000 · data as of November 13, 2026
Harvard Bioscience Inc. (HBIO) is a industrial company listed in the US with a market value of about $43M. In the twelve months to September 30, 2026 it had revenue of $89M and net income of -$12M, a net margin of -13.2%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).
Key numbers: a P/E of 1.1, 5-year revenue growth of -3% a year, a 5-year average ROIC of -18%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 64% below the current price.
About Harvard Bioscience
Harvard Bioscience is listed in the US and classified in biotechnology: laboratory analytical instruments, IPO year 2000. Revenue went from $109M in 2014 to $87M in 2025, a decline of about 2.0% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 7% over three years (dilution for shareholders). It spends 10% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Strong R&D investment or growth above 20%
- Stock-based pay below 5% of revenue
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $89M | $87M | $94M | $112M | $113M | $119M | $102M | $116M | $121M | $77M | $105M |
| Net income | -$12M | -$57M | -$12M | -$3M | -$10M | -$288000 | -$8M | -$5M | -$3M | -$865000 | -$4M |
| Free cash flow | -$3M | $5M | -$1M | $12M | -$438000 | $67000 | $8M | $7M | $2M | $167000 | — |
| EPS (diluted) | $8.88 | $-1.28 | $-0.28 | $-0.08 | $-0.23 | $-0.01 | $-0.20 | $-0.12 | $-0.08 | $-0.02 | $-0.13 |
| Net margin | -13.2% | -65.5% | -13.2% | -3.0% | -8.4% | -0.2% | -7.6% | -4.0% | -2.4% | -1.1% | -4.1% |
| ROIC | — | -82.7% | -4.5% | 1.3% | -4.3% | 1.2% | 0.1% | 0.2% | 0.4% | -0.5% | -2.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Harvard Bioscience’s P/E ratio?
About 1.1, based on the last twelve months of diluted earnings per share.
Is Harvard Bioscience stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 64% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Harvard Bioscience pay a dividend?
Not currently.
Is Harvard Bioscience a good stock to buy?
We do not give buy or sell advice. Harvard Bioscience scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.